Drugs / SG1827
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06076291 | Sep 2023 → Mar 2026 overdue | cancer | Hangzhou Sumgen Biotech Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SG1827 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06076291 ↗ |
| Route | Intravenous | “by IV infusion” NCT06076291 ↗ |